行情

GHDX

GHDX

基因组健康
NASDAQ

实时行情|Nasdaq Last Sale

70.68
-0.64
-0.90%
盘后: 70.68 0 0.00% 16:00 10/16 EDT
开盘
71.16
昨收
71.32
最高
71.33
最低
70.55
成交量
19.15万
成交额
--
52周最高
92.18
52周最低
50.77
市值
26.54亿
市盈率(TTM)
53.74
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

GHDX 新闻

  • 25 Stocks Moving in Tuesday's Pre-Market Session
  • Benzinga.1天前
  • Here's Why Genetic Testing Stocks Tumbled in September
  • MotleyFool.com.10/05 21:33
  • Inside Genomic Health's $3B deal: A false start, rejections and a mysterious last-minute bidder
  • American City Business Journals.10/05 03:09
  • Faruqi & Faruqi, LLP Announces Filing of a Class Action Lawsuit Against Genomic Health, Inc. (GHDX)
  • PR Newswire.10/02 22:30

更多

所属板块

生物技术和医学研究
+0.24%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

GHDX 简况

Genomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test. Its research and development activities are focused on developing a pipeline of tests to optimize the treatment of various cancers including breast, colon, prostate and other cancers. It offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS), and a Genomic Prostate Score, for prostate cancer.
展开

Webull提供Genomic Health, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。